Race colors transplantation utilization for multiple myeloma
نویسندگان
چکیده
منابع مشابه
Autologous transplantation for multiple myeloma.
Until now high-dose therapy (HDT) supported by autologous stem cell transplantation (ASCT) has been considered the standard of care for frontline therapy of multiple myeloma (MM) in younger patients with normal renal function, and MM is currently the first indication of ASCT. However, the introduction of the novel agents thalidomide, bortezomib and lenalidomide is changing the scenario in two w...
متن کاملRace and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.
Blacks are twice as likely to develop and die from multiple myeloma (MM), and are less likely to receive an autologous hematopoietic-cell transplant (AHCT) for MM compared to Whites. The influence of race on outcomes of AHCT for MM is not well described. We compared the probability of overall survival (OS), progression-free survival (PFS), disease progression, and nonrelapse mortality (NRM) amo...
متن کاملMULTIPLE MYELOMA Stem cell transplantation in multiple myeloma
High-dose treatment (HDT) with autologous stem cell transplantation (ASCT) has been shown to increase survival and time to progression in multiple myeloma (IMM) compared with conventional chemotherapy. In the French IFM90-study [1], 200 patients were randomised to receive prolonged standard treatment with i.v. combination chemotherapy, or a short phase by induction treatment with the same regim...
متن کاملHematopoietic Cell Transplantation for Multiple Myeloma.
BACKGROUND: Multiple myeloma (MM) is a malignant plasma cell disorder with a median survival of three years. Despite the development of numerous conventional chemotherapy regimens and interferons, there has been little progress in improving the survival of patients with MM. Very high-dose chemoradiotherapy and autologous or allogeneic hematopoietic stem cell transplantation (HSCT) can result in...
متن کاملStem cell transplantation for multiple myeloma.
BACKGROUND Multiple myeloma (MM) is the second most common hematologic malignancy, affecting approximately 14,000 new patients in the United State per year. The median overall survival is 5 years, and cure is a realistic goal for only a small minority of patients. METHODS A review of the literature was conducted that focused on treatment strategies for MM involving administration of high dose...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer
سال: 2017
ISSN: 0008-543X
DOI: 10.1002/cncr.30750